Results 1 to 10 of about 27,063 (166)

The effects of neoadjuvant chemoradiotherapy-related frailty by analytic morphomics in esophageal cancer [PDF]

Journal of Cardiothoracic Surgery
Background Neoadjuvant chemoradiotherapy followed by surgery offers potential cure for locally advanced esophageal cancer. Yet, frailty often emerges post-therapy, heightening risks of delayed surgery and complications.
Chien-Hung Chiu, Jules Lin, Peng Zhang, Andrew C. Chang, Brian A. Derstine, Brian E Ross, Binu Enchakalody, Nidhi V. Shah, Yun-Hen Liu, Stewart C. Wang, Yin-Kai Chao   +10 more
doaj   +2 more sources

Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis

Frontiers in Oncology, 2022
ObjectivesTo evaluate the clinical curative effects and toxicity of neoadjuvant chemoradiotherapy for resectable gastric cancer compared to those of neoadjuvant chemotherapy.MethodsA systematic review and meta-analysis of the randomized controlled trials
Jiuzhou Chen, Jiuzhou Chen, Yaru Guo, Yaru Guo, Miao Fang, Miao Fang, Yan Yuan, Yan Yuan, Youqi Zhu, Youqi Zhu, Yong Xin, Yong Xin, Longzhen Zhang, Longzhen Zhang   +13 more
doaj   +3 more sources

The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer

Clinical and Translational Radiation Oncology, 2020
Background and purpose: With currently available techniques, the prediction of pathologic complete response after neoadjuvant chemoradiotherapy is insufficient.
Marije Slingerland, Gabi van Pelt
exaly   +3 more sources

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis

Frontiers in Oncology, 2023
BackgroundThere is increasing evidence that neoadjuvant chemoradiotherapy is superior to neoadjuvant chemotherapy for patients with locally advanced gastric cancer. However, a number of studies have come to the opposite conclusion.
Youqi Zhu, Youqi Zhu, Jiuzhou Chen, Jiuzhou Chen, Xueqing Sun, Xueqing Sun, Yufei Lou, Yufei Lou, Miao Fang, Miao Fang, Fengjuan Zhou, Lei Zhang, Yong Xin, Yong Xin   +13 more
doaj   +1 more source

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder [PDF]

Investigative and Clinical Urology, 2022
Purpose: To assess the safety and efficacy of gemcitabine and cisplatin as neoadjuvant chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive bladder cancer (MIBC).
Hyun Hwan Sung, Hana Kim , Ryul Kim, Chan Kyo Kim, Ghee Young Kwon, Won Park , Wan Song, Byong Chang Jeong, Se Hoon Park   +8 more
doaj   +1 more source

Neoadjuvant Chemoradiotherapy for Esophageal Cancer [PDF]

Archives of Surgery, 1998
With promising results from several institutions, many centers began treating patients with esophageal cancer with neoadjuvant chemoradiotherapy (NC) followed by esophagectomy. This approach is demanding for the patient and has not been proved to be better than esophagectomy alone.To assess survival time and measures of quality of life associated with ...
Tamim, Wael Z., Davidson, Robert S., Quinlan, Robert M., O'Shea, Michael A., Orr, Richard K., Swanson, Richard S.   +5 more
openaire   +3 more sources

Neoadjuvant chemoradiotherapy in rectal cancer [PDF]

memo - Magazine of European Medical Oncology, 2020
SummaryNeoadjuvant chemoradiotherapy is a well-established standard treatment for locally advanced rectal cancer and has led to a remarkable improvement in local control. However, distant recurrences still pose a notable threat and local failure, albeit increasingly rare, can lead to unfavorable clinical situations.
Christoph Reinhold Arnold, Julian Mangesius, Robert Jäger, Ute Ganswindt   +3 more
openaire   +1 more source

Impacts of neoadjuvant therapy on the number of dissected lymph nodes in esophagogastric junction cancer patients

BMC Gastroenterology, 2023
Background Neoadjuvant therapy favors the prognosis of various cancers, including esophagogastric junction cancer (EGC). However, the impacts of neoadjuvant therapy on the number of dissected lymph nodes (LNs) have not yet been evaluated in EGC.
Qi Wang, Jin-tong Ge, Hua Wu, Sheng Zhong, Qing-quan Wu   +4 more
doaj   +1 more source

Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients

Frontiers in Oncology, 2021
Programmed death 1(PD-1) blockade has shown promising efficacy in advanced gastric cancer. Here, we performed a retrospective analysis of three patients with locally advanced gastric cancer who received adjuvant PD-1 plus chemoradiotherapy as neoadjuvant
Jia Wei, Xiaofeng Lu, Qin Liu, Lin Li, Song Liu, Fangcen Liu, Yao Fu, Xiangshan Fan, Yang Yang, Chuang Qi, Yangyang Yu, Wenxian Guan, Baorui Liu   +12 more
doaj   +1 more source

Neoadjuvant chemotherapy with or without neoadjuvant radiotherapy compared with neoadjuvant chemoradiotherapy for esophageal cancer [PDF]

Journal of Thoracic Disease, 2018
Although it was controversial for treating locally advanced resectable esophageal squamous cell carcinoma (ESCC), neoadjuvant chemoradiotherapy (NACR) was more widely accepted rather than neoadjuvant chemotherapy (NAC) worldwide. With the development of paclitaxel, a high response rate to NAC was reported in many studies. Our hypothesis is that lots of
Yan, Zheng, Xianben, Liu, Ruixiang, Zhang, Zongfei, Wang, Haibo, Sun, Jianjun, Qin, Shilei, Liu, Yin, Li   +7 more
openaire   +2 more sources